|
Appendix
As noted previously (Laboratory/Animal/Preclinical Studies) samples of Cancell/Cantron/Protocel were evaluated in the National Cancer Institute's (NCI’s) in vitro 60 Human Tumor Cell Line Screen in 1990 and 1991. In the screen, the cell lines are grown in artificial media under conditions that do not truly mimic the in vivo situation in animals or humans. The important information used in assessing a drug’s effectiveness in the NCI in vitro screen includes drug concentrations necessary to achieve the following:
- 50% inhibition of cell growth (GI50; the concentration needed to reduce the growth of treated cells to half that of untreated [i.e., control] cells).
- 100% (total) growth inhibition (TGI; the concentration required to completely halt the growth of treated cells).
- 50% cell kill or lethal concentration (LC50; the concentration that kills 50% of treated cells).
The log10 values for GI50, TGI, and LC50 for the 60 cell lines are available online.
The variations in log10 values for GI50 are 0.4–1.8 (mean = 1.15), equivalent to concentrations of 2.5–63 μg /mL (mean = 14); the variations in log10 values for TGI are 1.0–2.5 (mean = 1.62), equivalent to 10–320 μg/mL (mean = 41); and the variations in log10 values for LC50 are 1.6–3.9 (mean = 3.17), equivalent to 39–7,943 μg/mL (mean = 1,479).
Cancell/Cantron/Protocel Tumor Cell Line Screen Results
|
Parameter Measured
|
60 Cell-line Range (μg/mL)
|
Mean (μg/mL)
|
| 50% growth inhibition (GI50) |
2.5–63 |
14 |
| Total growth inhibition (TGI) |
10–320 |
41 |
| Concentration for 50% lethality (LC50) |
39–7,943 |
1,479 |
| Maximum theoretical human plasma concentration (for comparison) |
— |
29 (calculated) |
Based on the manufacturer's recommended doses of a marketed brand of Cancell/Cantron/Protocel it has been calculated that under idealized conditions of absolutely no loss of the constituents after administration to a patient (i.e., 100% bioavailability, meaning no loss due to degradation, absorption in the body, or rapid excretion—an unlikely situation), the maximum concentration that could be achieved in the plasma of an average 154-lb male is 29 μg/mL (antilog of 1.46). Thus, under these highly idealized conditions Cancell/Cantron/Protocel may exhibit some mild inhibitory effect on the growth of some cancer cells, but it would not be expected to inhibit their growth completely or to kill them. There is little evidence that any of the constituents of Cancell/Cantron/Protocel would be available in the bloodstream of a patient.
Back to Top
< Previous Section | Next Section > |
